First Horizon Corporation’s ALPS Medical Breakthroughs ETF SBIO Stock Holding History

First Horizon Corporation’s Portfolio SBIO Stock Details SBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	$14K	Buy	+305	New	+$14.6K	﹤0.01%	618

Other funds holding SBIO

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

NAM

NTV Asset Management Charleston, West Virginia $910M AUM 27.02% 1-Year Est. Return

CCP

Cardan Capital Partners Denver, Colorado $893M AUM 22.82% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

First Horizon Corporation's SBIO Position: Q2 2021 in Review

First Horizon Corporation opened a new position in ALPS Medical Breakthroughs ETF (SBIO) in Q2 2021: 305 shares worth $14K. The stake represents ﹤0.01% of the portfolio and ranks #618 among its holdings.

66 funds tracked by Wall St. Rank hold SBIO as of Q2 2021.

First Horizon Corporation held 305 shares of ALPS Medical Breakthroughs ETF worth $14K as of Q2 2021.
ALPS Medical Breakthroughs ETF was a new First Horizon Corporation position in Q2 2021.
ALPS Medical Breakthroughs ETF made up ﹤0.01% of First Horizon Corporation's portfolio in Q2 2021, its #618 holding.
66 funds tracked by Wall St. Rank held ALPS Medical Breakthroughs ETF as of Q2 2021.

Based on First Horizon Corporation's 13F filing for Q2 2021, filed 9 Aug 2021.